Systemic sclerosis (scleroderma) is an autoimmune rheumatic disease with a high burden of morbidity and significant mortality due to organ based complications. Pathogenesis involves dysfunction of the immune system and vasculature leading to organ based fibrosis as well as Raynaud phenomenon and skin fibrosis. Survival is improving through systematic evaluation of internal organ complications and better treatment of manifestations such as scleroderma renal crisis and pulmonary arterial hypertension. The disease is clinically heterogeneous and successful management depends upon accurate diagnosis, classification and stratification of risk of cardiopulmonary complications. This session will use case-based discussion to illustrate current management approaches for this challenging multi-system disease.
Upon completion of this session, participants should be able to:
- discuss the classification of systemic sclerosis and its impact on treatment and prognosis
- apply cardiopulmonary testing to determine the relative contributions of lung fibrosis and pulmonary hypertension
- formulate a therapeutic regimen to address morbidity and mortality in systemic sclerosis and develop strategies for management of global disease and organ-based complications
To see other sessions for this day, use the date buttons to the left.